Brand Name | Status | Last Update |
---|---|---|
veletri | New Drug Application | 2022-11-28 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypertension | D006973 | EFO_0000537 | I10 | 1 | 1 | 3 | 7 | 3 | 15 |
Pulmonary arterial hypertension | D000081029 | — | — | 1 | — | 3 | 5 | 3 | 12 |
Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | — | 2 | 3 | 4 | 1 | 10 |
Familial primary pulmonary hypertension | D065627 | — | I27.0 | 1 | — | 3 | 3 | 2 | 9 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Vascular diseases | D014652 | EFO_0004264 | I77 | — | 1 | 3 | — | — | 4 |
Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 3 | — | — | 3 |
Respiratory tract diseases | D012140 | — | — | — | — | 3 | — | — | 3 |
Connective tissue diseases | D003240 | EFO_1001986 | M35 | — | — | 3 | — | — | 3 |
Lung diseases | D008171 | EFO_0003818 | J98.4 | — | — | 3 | — | — | 3 |
Liver transplantation | D016031 | EFO_0010682 | — | — | 1 | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Ischemia | D007511 | EFO_0000556 | — | 1 | 1 | — | — | — | 1 |
Wounds and injuries | D014947 | — | T14.8 | 1 | 1 | — | — | — | 1 |
Reperfusion injury | D015427 | — | — | 1 | 1 | — | — | — | 1 |
Delayed graft function | D051799 | — | — | 1 | 1 | — | — | — | 1 |
Persistent fetal circulation syndrome | D010547 | EFO_1001103 | P29.3 | — | 1 | — | — | — | 1 |
Systemic scleroderma | D012595 | EFO_0000717 | M34 | — | 1 | — | — | — | 1 |
Localized scleroderma | D012594 | EFO_1001361 | L94.0 | — | 1 | — | — | — | 1 |
Diffuse scleroderma | D045743 | EFO_0000404 | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Congenital heart defects | D006330 | — | Q24.9 | — | — | — | — | 1 | 1 |
Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | — | 1 | 1 |
Drug common name | Tezosentan |
INN | tezosentan |
Description | Tezosentan is a non-selective ETA and ETB receptor antagonist. It acts as a vasodilator and was designed by Actelion as a therapy for patients with acute heart failure. However, studies showed that tezosentan did not improve dyspnea or reduce the risk of fatal or nonfatal cardiovascular events.
|
Classification | Small molecule |
Drug class | endothelin receptor antagonists |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)C)cn2)nc(-c2ccnc(-c3nnn[nH]3)c2)nc1OCCO |
PDB | — |
CAS-ID | 180384-57-0 |
RxCUI | — |
ChEMBL ID | CHEMBL61780 |
ChEBI ID | — |
PubChem CID | 151174 |
DrugBank | — |
UNII ID | 64J9J55263 (ChemIDplus, GSRS) |